Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.460,08 +907,92 (+2,42%) EUR/USD
1,0700 -0,0005 (-0,04%) Bitcoin EUR
62.423,44 +230,77 (+0,37%) CMC Crypto 200
1.413,98 -10,12 (-0,71%)
Recursion Pharmaceuticals, Inc. (RXRX)
Dopo ore:
| Chiusura precedente | 7,60 |
| Aperto | 7,56 |
| Denaro | 7,68 x 1400 |
| Lettera | 7,74 x 300 |
| Min-Max giorno | 7,55 - 7,92 |
| Intervallo di 52 settimane | 4,54 - 16,75 |
| Volume | |
| Media Volume | 6.318.598 |
| Capitalizzazione | 1,807B |
| Beta (5 anni mensile) | 0,75 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,58 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,00 |
GlobeNewswireRecursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Citi's 18th Annual BioPharma Conference – September 6-7, 2023Citi's Global Technology Conference – September 6-8, 2023Cantor Global Healthcare Conference – September 26-28, 2023 About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company lead
GlobeNewswireRecursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achi
GlobeNewswireRecursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica’s MatchMaker technology.SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced i
